Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer — Stella

Recruiting

Back to Prostatic Neoplasms, Castration-Resistant trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

Australia

St. Vincent's Hospital Research Office-Translational Research Center, Darlinghurst

South Africa

Steve Biko Hospital-Department of Nuclear Medicine, Pretoria

Key details

Phase

Early testing

Sponsor

Endocyte

Enrollment target

~99 participants

Started

April 2021

Primary completion

January 2027

Age range

18 Years and older

Sex

Male only

Last updated March 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov